Alzheimer’s disease attacks the cells of the brain and neurotransmitters, affecting the way brain functions, memory and behaviour. There is no known cure for the disease, and current approaches focus on helping people maintain mental function, manage behavioural symptoms, and slow down specific problems, such as memory loss. Two categories of drugs are approved for Alzheimer’s disease treatment: cholinesterase inhibitors and partial N-methyl D-aspartate (NMDA) antagonists.
Some of the key facts of Alzheimer’s disease report1. Alzheimer’s Disease affects an estimated 6.08 million people in the United States.2. Approximately 200,000 people younger than 65 years constitute the younger-onset population of Alzheimer’s Disease in the US.3. The females show a higher proportion of Alzheimer’s Disease Prevalence as compared to males in the 7MM.
Scope of Alzheimer’s disease report
Request for sample pages
Table of contents
1. Key Insights
2. Executive Summary of Alzheimer’s disease (AD)
3. Alzheimer’s disease (AD): Disease Background and Overview
3.1. Introduction
3.2. Sign and Symptoms
3.3. Pathophysiology
3.4. Risk Factors
3.5. Diagnosis
4. Patient Journey
5. Epidemiology and Patient Population
5.1. Epidemiology Key Findings
5.2. Assumptions and Rationale: 7MM
5.3. Epidemiology Scenario: 7MM
5.3.1. Alzheimer’s disease (AD) Epidemiology Scenario in the 7MM (2017- 2030)
5.4. United States Epidemiology
5.4.1. Alzheimer’s disease (AD) Epidemiology Scenario in the United States (2017- 2030)
5.5. EU-5 Country-wise Epidemiology
5.5.1. Germany Epidemiology
5.5.1.1. Alzheimer’s disease (AD) Epidemiology Scenario in Germany (2017- 2030)
5.5.2. France Epidemiology
5.5.2.1. Alzheimer’s disease (AD) Epidemiology Scenario in France (2017- 2030)
5.5.3. Italy Epidemiology
5.5.3.1. Alzheimer’s disease (AD) Epidemiology Scenario in Italy (2017- 2030)
5.5.4. Spain Epidemiology
5.5.4.1. Alzheimer’s disease (AD) Epidemiology Scenario in Spain (2017- 2030)
5.5.5. United Kingdom Epidemiology
5.5.5.1. Alzheimer’s disease (AD) Epidemiology Scenario in the United Kingdom (2017-2030)
5.6. Japan Epidemiology
5.6.1. Alzheimer’s disease (AD) Epidemiology Scenario in Japan (2017- 2030)
6. Treatment Algorithm, Current Treatment, and Medical Practices
6.1. Alzheimer’s disease (AD) Treatment and Management
6.2. Alzheimer’s disease (AD) Treatment Algorithm
7. KOL Views
8. Unmet Needs
9. Appendix
9.1. Bibliography
9.2. Report Methodology
10. DelveInsight Capabilities
11. Disclaimer
12. About DelveInsight
Media ContactCompany Name: DelveInsightContact Person: Priya MauryaEmail: Send EmailPhone: +919650213330City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/